Alternating electric field therapy

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NovoCure Limited (NVCR) on Behalf of Investors

Retrieved on: 
Friday, June 16, 2023
Class Action Lawsuit, Professional Services, Legal, Telephone, Clinical trial, Suite, Alternating electric field therapy, Patient, Standard of care, News, Lung cancer

Law Offices of Howard G. Smith announces an investigation on behalf of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR ) investors concerning the Company’s possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR ) investors concerning the Company’s possible violations of federal securities laws.
  • On June 6, 2023, NovoCure announced “positive results” from the clinical trial evaluating its Tumor Treating Fields therapy in treating non-small cell lung cancer.
  • On this news, NovoCure’s stock price fell $35.51, or 43%, to close at $47.00 per share on June 6, 2023, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Law Offices of Frank R. Cruz Announces Investigation of NovoCure Limited (NVCR) on Behalf of Investors

Retrieved on: 
Thursday, June 15, 2023
Class Action Lawsuit, Professional Services, Legal, Clinical trial, Suite, Alternating electric field therapy, Law, Patient, Standard of care, News, Lung cancer

The Law Offices of Frank R. Cruz announces an investigation of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR ) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR ) on behalf of investors concerning the Company’s possible violations of federal securities laws.
  • If you are a shareholder who suffered a loss, click here to participate.
  • On this news, NovoCure’s stock price fell $35.51, or 43%, to close at $47.00 per share on June 6, 2023, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Novocure Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 4, 2023
Pharmaceutical, Health, Oncology, Clinical Trials, Pancreatic cancer, Partnership, Loss, Brain, MacLean Center for Clinical Medical Ethics, Regulation Fair Disclosure, Information technology, Temozolomide, Marketing, Prescription, Senior, Survival, American Society of Clinical Oncology, Clinical trial, Disclosure, Cancer, History, Lung cancer, Immunotherapy, Associate, EDT, Glioblastoma, EBITDA, Patient, Investment, Weill Cornell Medicine, Webcast, CDT, Research, METIS, Society, Regulation, Pharmaceutical industry, Fine chemical, Cryptocurrency, Alternating electric field therapy, NSCLC

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2023.
  • “The first quarter was another period of solid progress for Novocure,” said Asaf Danziger, Novocure’s Chief Executive Officer.
  • Novocure will host an investor event at 2:00 p.m. CDT on June 6 featuring leading thoracic oncologists, investigators and Novocure leadership.
  • Data from phase 3 LUNAR clinical trial in NSCLC (ASCO Annual Meeting, June 6, 2023)
    Novocure will host a conference call and webcast to discuss first quarter 2023 financial results at 8:00 a.m. EDT today, Thursday, May 4, 2023.

Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France

Retrieved on: 
Wednesday, March 1, 2023
Oncology, Medical Devices, Health, Other Health, General Health, Biotechnology, Skin, Social, III, Official Journal, Temozolomide, TMZ, LPPR, Patient, Progression-free survival, Commission nationale de l'informatique et des libertés, Neoplasm, ASA, Official Journal of the European Union, HR, GBM, Glioblastoma, CE, Physician, Light, Medical imaging, Nursing, Alternating electric field therapy

Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in France.

Key Points: 
  • Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in France.
  • "We are pleased to make Optune available to French patients and healthcare professionals for the treatment of glioblastoma,” said Anne Calixte de Lembeye, General Manager of Novocure France.
  • We are energized and prepared to support patients in France as they begin to use our therapy as an additional treatment choice for newly diagnosed GBM."
  • “We are proud that Optune is now a treatment choice for newly diagnosed GBM patients in France.

Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Retrieved on: 
Tuesday, November 29, 2022
Oncology, Medical Devices, Health, Health Technology, General Health, Biotechnology, Patient, Temozolomide, Glioblastoma, Radiation therapy, Health Canada, Neoplasm, GBM, Chlorine, Survival, HR, Light, Medical device, Medical imaging, Radiology, Alternating electric field therapy

Novocure (NASDAQ: NVCR) today announced that Health Canada has approved Optune for the treatment of newly diagnosed and recurrent glioblastoma (GBM).

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced that Health Canada has approved Optune for the treatment of newly diagnosed and recurrent glioblastoma (GBM).
  • Optune is the first treatment for glioblastoma approved in Canada in over 12 years.
  • Were very happy that Health Canada has approved Optune for the treatment of GBM, said Jovan Antunovic, Country Manager of Novocure Canada.
  • Novocures phase 3 pivotal EF-14 trial compared Optune plus temozolomide to temozolomide alone in 695 patients with newly diagnosed GBM.

Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference

Retrieved on: 
Wednesday, November 23, 2022
Science, Neurology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Mesothelioma, Large-cell lung carcinoma, Survival, Stomach, Conference, Cancer, Glioblastoma, Ovarian cancer, Annual report, Disclosure, Pancreatic cancer, Liver cancer, EST, COVID-19, Regulation, Regulation Fair Disclosure, Alternating electric field therapy, Patient

Novocure (NASDAQ: NVCR) announced today it will participate in the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022.

Key Points: 
  • Novocure (NASDAQ: NVCR) announced today it will participate in the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022.
  • Novocures corporate presentation is updated periodically, and the current presentation can be accessed from the Investor Relations page of Novocures website, www.novocure.com/investor-relations .
  • Novocure has used, and intends to continue to use, its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
  • Novocures commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma.

Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada

Retrieved on: 
Tuesday, November 15, 2022
Biotechnology, Health, Oncology, Clinical Trials, Radiation therapy, Mesothelioma, Investment, Large-cell lung carcinoma, Hospital, Medical Affairs Bureau, Radiation, Survival, Stomach, Multimedia, Science, Quality of life, Cancer, Glioblastoma, Ovarian cancer, Annual report, Pancreatic cancer, Liver cancer, COVID-19, Alternating electric field therapy, Marketing communications, PARP, Patient, Medical imaging, Radiology

Novocure (NASDAQ: NVCR) today announced it has opened a new office in Montreal to expand and support its growing business in Canada.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced it has opened a new office in Montreal to expand and support its growing business in Canada.
  • Were very proud to say that Montreal is now home for Novocure Canada, said Jovan Antunovic, Country Manager of Novocure Canada.
  • We have a great opportunity to grow our business and bring our therapy to more patients who can benefit throughout Canada.
  • While Novocures physical office presence in Canada is new, Novocures footprint in Canada began in 2013, when Canadian institutions began participating in Novocures clinical trials evaluating TTFields.

Novocure Secures CE Mark for New Array

Retrieved on: 
Friday, November 11, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Liver cancer, Radiation, Ovarian cancer, Survival, Annual report, NASDAQ, CE marking, U.S. Securities and Exchange Commission, Cancer, Toxicity, Adult, PARP, Mesothelioma, Stomach, Patient, Glioblastoma, Forward-looking statement, Private Securities Litigation Reform Act, Large-cell lung carcinoma, Pancreatic cancer, New product development, COVID-19, Alternating electric field therapy, Medical imaging

Novocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, designed for more efficient Tumor Treating Fields delivery and greater comfort for patients with glioblastoma.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, designed for more efficient Tumor Treating Fields delivery and greater comfort for patients with glioblastoma.
  • Through product innovation, our goal is to deliver higher intensity TTFields to targeted regions without adding toxicity.
  • We believe the new arrays have the potential to meaningfully improve both patient comfort and efficacy of our therapy.
  • With CE Mark for the new arrays, the company will begin a limited market release in Europe.

Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy

Retrieved on: 
Thursday, October 20, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Physician, LinkedIn, Stomach, U.S. Securities and Exchange Commission, Pancreatic cancer, Mesothelioma, PARP, Science, Private Securities Litigation Reform Act, Annual report, NASDAQ, Patient, Alternating electric field therapy, Twitter, Liver cancer, Cancer, Awareness, Adult, Survival, Forward-looking statement, Radiation, Glioblastoma, COVID-19, Ovarian cancer, Large-cell lung carcinoma, Medical imaging

Novocure (NASDAQ: NVCR) today announced the launch of a campaign intended to drive awareness and understanding of Tumor Treating Fields (TTFields) therapy as a distinct anticancer modality and an emerging cornerstone of solid tumor treatment.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced the launch of a campaign intended to drive awareness and understanding of Tumor Treating Fields (TTFields) therapy as a distinct anticancer modality and an emerging cornerstone of solid tumor treatment.
  • Were excited to launch this campaign to drive awareness and help the oncology community understand the science of Tumor Treating Fields, said Novocures Chief Commercial Officer Pritesh Shah.
  • Broadening understanding of our therapy is key in bringing Tumor Treating Fields therapy to more patients who can benefit globally.
  • To learn more about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfieldstherapy.com .

Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology

Retrieved on: 
Thursday, October 20, 2022
Oncology, Health, Communications, General Health, Pharmaceutical, Publishing, Biotechnology, Stomach, LinkedIn, U.S. Securities and Exchange Commission, Pancreatic cancer, Mesothelioma, PARP, Assistant, Review, MD Anderson Cancer Center, Private Securities Litigation Reform Act, Annual report, Patient, Shams, Alternating electric field therapy, Osteopathic medicine in the United States, Research, Twitter, Division, Rowan University School of Osteopathic Medicine, Liver cancer, Cancer, Doctor of Philosophy, Department, Mitosis, Adult, Survival, Forward-looking statement, DNA, Radiation, University, Glioblastoma, COVID-19, Gene, Ovarian cancer, Large-cell lung carcinoma, Pharmaceutical industry, Medical imaging, Neoplasm, MD

TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.

Key Points: 
  • TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.
  • The review article cites that many studies to date have focused on TTFields effect on cancer cell division.
  • Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.
  • Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.